Previous close | 131.75 |
Open | 132.00 |
Bid | 131.76 x 1200 |
Ask | 131.78 x 900 |
Day's range | 131.08 - 132.42 |
52-week range | 99.14 - 133.10 |
Volume | |
Avg. volume | 8,735,054 |
Market cap | 333.903B |
Beta (5Y monthly) | 0.38 |
PE ratio (TTM) | 941.71 |
EPS (TTM) | 0.14 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 3.08 (2.34%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | 136.06 |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
RAHWAY, N.J., March 28, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adults.